BiotechTube

OFC Infusion + FC infusion

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukaemia, Lymphocytic, Chronic

Conditions

Leukaemia, Lymphocytic, Chronic

Trial Timeline

Mar 12, 2009 → Oct 25, 2017

NCT ID
NCT00824265

About OFC Infusion + FC infusion

OFC Infusion + FC infusion is a phase 3 stage product being developed by Novartis for Leukaemia, Lymphocytic, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT00824265. Target conditions include Leukaemia, Lymphocytic, Chronic.

What happened to similar drugs?

2 of 7 similar drugs in Leukaemia, Lymphocytic, Chronic were approved

Approved (2) Terminated (3) Active (2)
✅AcalabrutinibAstraZenecaApproved
✅OfatumumabGenmabApproved
❌chlorambucil, tablets + ofatumumab (GSK1841157) infusionNovartisPhase 3
🔄Ofatumumab + Physicians' ChoiceNovartisPhase 3
❌NilotinibNovartisPhase 3
❌OfatumumabNovartisPhase 3
🔄Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00824265Phase 3Completed

Competing Products

20 competing products in Leukaemia, Lymphocytic, Chronic

See all competitors
ProductCompanyStageHype Score
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
39
AZD1152 + C14 AZD1152AstraZenecaPhase 1
29
AcalabrutinibAstraZenecaApproved
50
AZD2811 + Azacitidine + VenetoclaxAstraZenecaPhase 1
21
Administration of AZD6738AstraZenecaPhase 1
29
AZD1152AstraZenecaPhase 1
29
AZD0486 + Prednisone (or equivalent) + Rituximab + Cyclophosphamide + Vincristine + Doxorubicin + AcalabrutinibAstraZenecaPhase 1/2
39
AZD2171AstraZenecaPhase 1
29
Nilotinib, Pegylated interferon alpha-2b, ImatinibMerckPhase 2
35
chlorambucil, tablets + ofatumumab (GSK1841157) infusionNovartisPhase 3
32
Ofatumumab + Physicians' ChoiceNovartisPhase 3
40
NilotinibNovartisPhase 3
32
OfatumumabNovartisPhase 3
32
Daunorubicin + Cytarabine + Eltrombopag + PlaceboNovartisPhase 2
35
BlinatumomabAmgenPhase 1
29
Idelalisib + RituximabGilead SciencesPre-clinical
26
humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumabGilead SciencesPhase 1/2
28
BosulifPfizerPhase 2
31
Bosutinib + Imatinib + Nilotinib + Dasatinib + PonatinibPfizerPre-clinical
26
Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3
47